Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 16:13:17588359211001199.
doi: 10.1177/17588359211001199. eCollection 2021.

Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials

Ramez N Eskander  1 , Matthew A Powell  2
Affiliations
Review

Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials

Ramez N Eskander et al. Ther Adv Med Oncol. .

Abstract

The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise, particularly in biomarker select populations. In an effort to improve oncologic outcomes, investigators are exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale and design of current phase III immuno-oncology clinical trials in patients with advanced stage or recurrent endometrial cancer.

Keywords: antiangiogenic therapy; chemotherapy; combination therapy; endometrial cancer; immune checkpoint inhibition; immunotherapy; tumor mutational burden.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr. Eskander has received consulting and honoraria fees from Genentech, AstraZeneca Oncology, Clovis Oncology, Pfizer and Merck. Dr. Powell has received consulting fees from Merck, Eisai, AstraZeneca, Clovis Oncology, Tesaro/GSK.

References

    1. Siegel RL, Miller KD, Fuchs HE, et al.. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7–33. - PubMed
    1. Miller DS, Filiaci VL, Mannel RS, et al.. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol 2020; 38: 3841–3850. - PMC - PubMed
    1. Slomovitz BM, Jiang Y, Yates MS, et al.. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015; 33: 930–936. - PMC - PubMed
    1. Fader AN, Roque DM, Siegel E, et al.. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018; 36: 2044–2051. - PubMed
    1. Fader AN, Roque DM, Siegel E, et al.. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 2020; 26: 3928–3935. - PMC - PubMed

LinkOut - more resources